Arno Therapeutics, Inc.
ARNI · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $15 | $13 | $9 |
| G&A Expenses | $5 | $7 | $3 | $2 |
| SG&A Expenses | $5 | $7 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $21 | $17 | $11 |
| Operating Income | -$13 | -$21 | -$17 | -$11 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $29 | -$23 | -$4 |
| Pre-Tax Income | -$12 | $8 | -$40 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | $8 | -$58 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0.57 | 0.38 | -7.75 | -4.57 |
| % Growth | -250% | 104.9% | -69.6% | – |
| EPS Diluted | -0.57 | 0.31 | -7.75 | -4.57 |
| Weighted Avg Shares Out | 20 | 20 | 8 | 5 |
| Weighted Avg Shares Out Dil | 20 | 25 | 8 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $19 | $6 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$13 | -$21 | -$17 | -$14 |
| % Margin | – | – | – | – |